Featured Product
This Week in Quality Digest Live
Health Care Features
Doug Folsom
Unpatched vulnerabilities will become increasingly susceptible to cyberattacks
Dirk Dusharme @ Quality Digest
Companies say they plan to pull some or all of their devices
Alex Waddell
Evidence points to what’s needed at individual and organizational levels
James Gaines
After decades of merely assisting doctors, are sophisticated machines ready to take charge?
Jon Speer
Fix issues that expose you to risk when it’s less expensive and time-consuming

More Features

Health Care News
Easy, reliable leak testing with methylene blue
New medical product from Canon’s Video Sensing Division
Reduce identifying info in patient health data to enable better treatments and diagnostics
Making the new material freely available to testing laboratories and manufacturers worldwide
Google Docs collaboration, more efficient management of quality deviations
MIT course focuses on the impact of increased longevity on systems and markets
Delivers time, cost, and efficiency savings while streamlining compliance activity
First responders may benefit from NIST contest to reward high-quality incident command dashboards
Enhances clinical data management for medtech companies

More News

Quality Digest

Health Care

Chip on a Card Would Detect Covid-19 Antibodies in a Minute

‘Completely new diagnostic platform’ could prove to be a valuable clinical tool for detecting exposure to multiple viruses

Published: Wednesday, February 10, 2021 - 12:00

(University of Rochester: Rochester, NY) -- Researchers in Rochester are developing an optical chip on a disposable card that can detect exposure to multiple viruses within a minute—including the coronavirus that causes Covid-19—from a single drop of blood.

Led by University of Rochester Medical Center researcher Benjamin Miller, the $1.7 million project is funded by the U.S. Department of Defense Manufacturing Technology Program using CARES Act funds through a contract with AIM Photonics. The collaboration also involves Ortho Clinical Diagnostics, which develops and manufactures innovative laboratory testing and blood-typing solutions at its Global Center for R&D Excellence in Rochester; Syntec Optics, a maker of polymer optics in Rochester; researchers at the NY CREATES 300 mm microelectronics research facility in Albany, New York, and at the University of California at Santa Barbara; and the Naval Research Laboratory in Washington, D.C.

“This is a completely new diagnostic platform,” says Miller, the Dean’s Professor of Dermatology and a professor of biomedical engineering, optics, and biochemistry and biophysics. “We think this is going to be valuable in very broad applications for clinical diagnostics, not just Covid-19.”


Rochester researchers are developing an optical chip on a disposable card that can detect exposure to multiple viruses—including the coronavirus that causes Covid-19—within a minute and from a single drop of blood. (Courtesy of the Miller Lab)

Key to the technology is an optical chip, no larger than a grain of rice. Proteins associated with eight different viruses, including SARS-CoV-2, are contained in separate sensor areas of the chip. If someone has been exposed to any of the viruses, antibodies to those viruses in the blood sample will be drawn to the proteins and detected.

Antibodies are proteins produced by the immune system to fight off specific bacteria and viruses. They remain in the immune system even after a patient recovers from an infection.

“It is exciting to see the sensors work developed by AIM Photonics, over the past five years, now play a part in more effective testing for Covid-19 and future diseases,” says Michael Cumbo, CEO of AIM Photonics. “The industry, academic, and government partnership is a fundamental piece of this institute. Together, we foster successful technology developments such as this optical chip, which in turn enables a very innovative diagnostic platform.”

The card will enable clinicians not only to detect and study Covid-19, but also to better understand potential relationships between Covid-19 infection and previous infections and immunity to other respiratory viruses, including circulating coronaviruses that cause the common cold.

“But one of the attractive aspects of this is there’s a pathway for this technology to eventually be used in a doctor’s office or a pharmacy,” Miller says.

“Our goal is to have a validated benchtop prototype by this winter, early spring at the latest.”

The researchers will use blood drawn from 100 consenting convalescent Covid-19 patients to test the device’s effectiveness.

When the researchers complete and validate the initial prototype, they will be able to apply for up to $5.3 million in additional funding to move the technology closer to commercial availability.

Discuss

About The Author

Quality Digest’s picture

Quality Digest

For 40 years Quality Digest has been the go-to source for all things quality. Our newsletter, Quality Digest, shares expert commentary and relevant industry resources to assist our readers in their quest for continuous improvement. Our website includes every column and article from the newsletter since May 2009 as well as back issues of Quality Digest magazine to August 1995. We are committed to promoting a view wherein quality is not a niche, but an integral part of every phase of manufacturing and services.